血清可不同程度地改变棘白菌素类药物的抗真菌特性。
Serum differentially alters the antifungal properties of echinocandin drugs.
作者信息
Paderu Padmaja, Garcia-Effron Guillermo, Balashov Sergey, Delmas Guillaume, Park Steven, Perlin David S
机构信息
Public Health Research Institute, 225 Warren St., Newark, NJ 07103, USA.
出版信息
Antimicrob Agents Chemother. 2007 Jun;51(6):2253-6. doi: 10.1128/AAC.01536-06. Epub 2007 Apr 9.
Abstract
Antifungal efficacies of the echinocandin drugs caspofungin, micafungin, and anidulafungin were reduced significantly in the presence of 50% human serum, which yielded nearly equivalent MICs or minimum effective concentrations against diverse Candida spp. and Aspergillus spp. Consistent with a direct drug interaction, serum decreased the sensitivity of glucan synthase to echinocandin drugs.
摘要
在存在50%人血清的情况下，棘白菌素类药物卡泊芬净、米卡芬净和阿尼芬净的抗真菌效力显著降低，这导致其对多种念珠菌属和曲霉属产生几乎相同的MIC（最低抑菌浓度）或最低有效浓度。与直接的药物相互作用一致，血清降低了葡聚糖合酶对棘白菌素类药物的敏感性。
相似文献
1
Serum differentially alters the antifungal properties of echinocandin drugs.
Antimicrob Agents Chemother. 2007 Jun;51(6):2253-6. doi: 10.1128/AAC.01536-06. Epub 2007 Apr 9.
2
Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis.
J Antimicrob Chemother. 2006 Apr;57(4):705-8. doi: 10.1093/jac/dkl022. Epub 2006 Feb 7.
3
Micafungin: a new echinocandin.
Clin Infect Dis. 2006 Apr 15;42(8):1171-8. doi: 10.1086/501020. Epub 2006 Mar 14.
4
The echinocandins.
Pharmacotherapy. 2007 Mar;27(3):369-88. doi: 10.1592/phco.27.3.369.
5
Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase.
Antimicrob Agents Chemother. 2007 May;51(5):1876-8. doi: 10.1128/AAC.00067-07. Epub 2007 Feb 26.
6
Candida albicans and Candida dubliniensis respond differently to echinocandin antifungal agents in vitro.
Antimicrob Agents Chemother. 2007 May;51(5):1882-4. doi: 10.1128/AAC.01525-06. Epub 2007 Feb 16.
7
Acquired resistance to echinocandins in Candida albicans: case report and review.
J Antimicrob Chemother. 2007 Jun;59(6):1076-83. doi: 10.1093/jac/dkm095. Epub 2007 Apr 27.
8
9
Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
Antimicrob Agents Chemother. 2005 Aug;49(8):3264-73. doi: 10.1128/AAC.49.8.3264-3273.2005.
10
FR209602 and related compounds, novel antifungal lipopeptides from coleophoma crateriformis no. 738. II. In vitro and in vivo antifungal activity.
J Antibiot (Tokyo). 2006 Mar;59(3):145-8. doi: 10.1038/ja.2006.21.
引用本文的文献
1
In Vitro Susceptibility Tests in the Context of Antifungal Resistance: Beyond Minimum Inhibitory Concentration in spp.
J Fungi (Basel). 2023 Dec 12;9(12):1188. doi: 10.3390/jof9121188.
2
Development of an in vitro pharmacokinetic/pharmacodynamic model in the presence of serum for studying micafungin activity against Candida albicans: a need for revision of CLSI susceptibility breakpoints.
J Antimicrob Chemother. 2023 Jun 1;78(6):1386-1394. doi: 10.1093/jac/dkad096.
3
Saliva for Precision Dosing of Antifungal Drugs: Saliva Population PK Model for Voriconazole Based on a Systematic Review.
Front Pharmacol. 2020 Jun 12;11:894. doi: 10.3389/fphar.2020.00894. eCollection 2020.
4
Antifungal Resistance and Tolerance in Bloodstream Infections: The Triad Yeast-Host-Antifungal.
Microorganisms. 2020 Jan 22;8(2):154. doi: 10.3390/microorganisms8020154.
5
Spontaneous Mutational Frequency and Mutation Rates Vary by Echinocandin Agent against .
Antimicrob Agents Chemother. 2018 Dec 21;63(1). doi: 10.1128/AAC.01692-18. Print 2019 Jan.
6
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.
Antimicrob Agents Chemother. 2017 Mar 24;61(4). doi: 10.1128/AAC.02068-16. Print 2017 Apr.
7
Albumin Enhances Caspofungin Activity against Aspergillus Species by Facilitating Drug Delivery to Germinating Hyphae.
Antimicrob Agents Chemother. 2015 Dec 7;60(3):1226-33. doi: 10.1128/AAC.02026-15.
8
Mechanisms of echinocandin antifungal drug resistance.
Ann N Y Acad Sci. 2015 Sep;1354(1):1-11. doi: 10.1111/nyas.12831. Epub 2015 Jul 17.
9
Repurposing FDA approved drugs against the human fungal pathogen, Candida albicans.
Ann Clin Microbiol Antimicrob. 2015 Jun 9;14:32. doi: 10.1186/s12941-015-0090-4.
10
Echinocandin resistance, susceptibility testing and prophylaxis: implications for patient management.
Drugs. 2014 Sep;74(14):1573-85. doi: 10.1007/s40265-014-0286-5.
本文引用的文献
1
Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates.
Antimicrob Agents Chemother. 2005 Aug;49(8):3264-73. doi: 10.1128/AAC.49.8.3264-3273.2005.
2
Caspofungin uptake is mediated by a high-affinity transporter in Candida albicans.
Antimicrob Agents Chemother. 2004 Oct;48(10):3845-9. doi: 10.1128/AAC.48.10.3845-3849.2004.
3
Micafungin.
Ann Pharmacother. 2004 Oct;38(10):1707-21. doi: 10.1345/aph.1D301. Epub 2004 Aug 31.
4
Disposition of caspofungin: role of distribution in determining pharmacokinetics in plasma.
Antimicrob Agents Chemother. 2004 Mar;48(3):815-23. doi: 10.1128/AAC.48.3.815-823.2004.
5
Echinocandin antifungal drugs.
Lancet. 2003 Oct 4;362(9390):1142-51. doi: 10.1016/S0140-6736(03)14472-8.
6
The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy.
Expert Opin Investig Drugs. 2003 Aug;12(8):1313-33. doi: 10.1517/13543784.12.8.1313.
7
In vitro activity of micafungin (FK-463) against Candida spp.: microdilution, time-kill, and postantifungal-effect studies.
Antimicrob Agents Chemother. 2002 Dec;46(12):3846-53. doi: 10.1128/AAC.46.12.3846-3853.2002.
8
Caspofungin acetate: an antifungal agent.
Am J Health Syst Pharm. 2001 Jul 1;58(13):1206-14; quiz 1215-7. doi: 10.1093/ajhp/58.13.1206.
9
Efficacy of oral cochleate-amphotericin B in a mouse model of systemic candidiasis.
Antimicrob Agents Chemother. 2000 Sep;44(9):2356-60. doi: 10.1128/AAC.44.9.2356-2360.2000.
10
Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872).
Antimicrob Agents Chemother. 1997 Nov;41(11):2339-44. doi: 10.1128/AAC.41.11.2339.
Zotero 插件